united therapeutics glp-1 receptor agonist Oral GLP-1-Based in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 receptor agonists and next-generation
Description
Moreover, the duration of impact on gastrin secretion after stopping medication is markedly different due to differences in pharmacokinetic profiles
Additional research showed that Rehmannia glutinosa use for 5 weeks improved impaired glucose tolerance, increased liver and muscle glycogen
Journal of Clinical Endocrinology & Metabolism , 109(4), 12341246
Microbial enterotypes and weight loss: results from a randomized controlled trial
doi: 10.1111/dom.12932
